SI-BONE (NASDAQ:SIBN) has announced the first in-patient procedures using its iFuse TORQ TNT Implant System (TNT), designed to address anatomic and biomedical challenges of pelvic fragility fractures as opposed to traditional cannulated screws.
TNT, an FDA-designated breakthrough device that received 510(k) clearance in August 2024, is the first 3D-printed transiliac-transsacral screw cleared for market in the U.S. Featuring a pelvis-specific design, the device aims to improve initial fixation and reduce the risk of screw backout.
One of the first surgeons to use TNT was Edward Westrick, MD, at Allegheny General Hospital in Pittsburgh, PA. “TNT went beyond my expectations,” said Dr. Black. “The streamlined instrumentation and implant design not only provided excellent fixation but also allowed for quick, precise implantation. This efficiency is critical when treating patients with fragile bones, as it reduces operating time, minimizes risks, and leads to faster recovery.”
In 2009, SI-BONE pioneered minimally invasive surgery of the SI joint and has since supported more than 3,900 surgeons in performing over 100,000 sacropelvic procedures. The company claims clinical evidence supports its technologies, including two randomized controlled trials and more than 135 peer-reviewed publications.
